{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:48:47Z","timestamp":1782827327930,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-17-CONV-0002"],"award-info":[{"award-number":["ANR-17-CONV-0002"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA21154"],"award-info":[{"award-number":["CA21154"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41417-026-01026-7","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:04:12Z","timestamp":1775747052000},"page":"427-439","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of ribosomal protein eL21 as a novel externalized protein and a target in triple-negative breast cancer"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1290-4603","authenticated-orcid":false,"given":"Lucie","family":"Arnould","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1633-8730","authenticated-orcid":false,"given":"Nina","family":"Radosevic-Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Duranton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8056-4584","authenticated-orcid":false,"given":"J\u00e9r\u00e9my","family":"N\u00e9ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-5492","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9rique","family":"Penault-Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Alexandra","family":"Albaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8255-9091","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Catez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"1026_CR1","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121:2750\u201367. https:\/\/doi.org\/10.1172\/JCI45014.","journal-title":"J Clin Investig"},{"key":"1026_CR2","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/1078-0432.CCR-18-2782","volume":"25","author":"KT Hwang","year":"2019","unstructured":"Hwang KT, Kim J, Jung J, Chang JH, Chai YJ, Oh SW, et al. Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database. Clin Cancer Res. 2019;25:1970\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2782.","journal-title":"Clin Cancer Res"},{"key":"1026_CR3","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045.","journal-title":"Clin Cancer Res"},{"key":"1026_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176\u201398. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1177.","journal-title":"Cancer Discov"},{"key":"1026_CR5","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2217\/pgs-2017-0117","volume":"18","author":"JR Jhan","year":"2017","unstructured":"Jhan JR, Andrechek ER. Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics. 2017;18:1595\u2013609. https:\/\/doi.org\/10.2217\/pgs-2017-0117.","journal-title":"Pharmacogenomics"},{"key":"1026_CR6","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","volume":"28","author":"DP Silver","year":"2010","unstructured":"Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28:1145\u201353. https:\/\/doi.org\/10.1200\/JCO.2009.22.4725.","journal-title":"J Clin Oncol"},{"key":"1026_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bbacli.2015.03.003","volume":"3","author":"EA O\u2019Reilly","year":"2015","unstructured":"O\u2019Reilly EA, Gubbins L, Sharma S, Tully R, Guang MHZ, Weiner-Gorzel K, et al. The fate of chemoresistance in triple-negative breast cancer (TNBC). BBA Clin. 2015;3:257\u201375. https:\/\/doi.org\/10.1016\/j.bbacli.2015.03.003.","journal-title":"BBA Clin"},{"key":"1026_CR8","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.breast.2017.06.023","volume":"34","author":"L Wein","year":"2017","unstructured":"Wein L, Loi S. Mechanisms of resistance to chemotherapy in early-stage triple-negative breast cancer (TNBC). Breast. 2017;34:S27\u201330. https:\/\/doi.org\/10.1016\/j.breast.2017.06.023.","journal-title":"Breast"},{"key":"1026_CR9","doi-asserted-by":"publisher","first-page":"82889","DOI":"10.18632\/oncotarget.12658","volume":"7","author":"K Takai","year":"2016","unstructured":"Takai K, Le A, Weaver VM, Werb Z. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget. 2016;7:82889\u2013901. https:\/\/doi.org\/10.18632\/oncotarget.12658.","journal-title":"Oncotarget"},{"key":"1026_CR10","doi-asserted-by":"publisher","first-page":"11091","DOI":"10.1073\/pnas.1222251110","volume":"110","author":"S Loi","year":"2013","unstructured":"Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ, et al. CD73 promotes anthracycline resistance and poor prognosis in triple-negative breast cancer. Proc Natl Acad Sci USA 2013;110:11091\u20136. https:\/\/doi.org\/10.1073\/pnas.1222251110.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1026_CR11","first-page":"1233","volume":"22","author":"C Anders","year":"2008","unstructured":"Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncology. 2008;22:1233\u20139.","journal-title":"Oncology"},{"key":"1026_CR12","first-page":"49","volume":"8","author":"UH Weidle","year":"2011","unstructured":"Weidle UH, Maisel D, Klostermann S, Schiller C, Weiss EH. Intracellular proteins displayed on the surface of tumor cells as targets for therapeutic intervention with antibody-related agents. Cancer Genom Proteom. 2011;8:49\u201363.","journal-title":"Cancer Genom Proteom"},{"key":"1026_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3390\/cancers10110452","volume":"10","author":"MA Albaret","year":"2018","unstructured":"Albaret MA, Vermot-Desroches C, Par\u00e9 A, Roca-Martinez JX, Malet L, Esseily J, et al. Externalized keratin 8: a target at the interface of microenvironment and intracellular signaling in colorectal cancer cells. Cancers. 2018;10:452. https:\/\/doi.org\/10.3390\/cancers10110452.","journal-title":"Cancers"},{"key":"1026_CR14","doi-asserted-by":"publisher","first-page":"21229","DOI":"10.3390\/ijms151121229","volume":"15","author":"M Didiasova","year":"2014","unstructured":"Didiasova M, Wujak L, Wygrecka M, Zakrzewicz D. From plasminogen to plasmin: role of plasminogen receptors in human cancer. Int J Mol Sci. 2014;15:21229\u201352. https:\/\/doi.org\/10.3390\/ijms151121229.","journal-title":"Int J Mol Sci"},{"key":"1026_CR15","doi-asserted-by":"publisher","first-page":"25684","DOI":"10.1074\/jbc.271.41.25684","volume":"271","author":"TA Hembrough","year":"1996","unstructured":"Hembrough TA, Li L, Gonias SL. Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J Biol Chem. 1996;271:25684\u201391. https:\/\/doi.org\/10.1074\/jbc.271.41.25684.","journal-title":"J Biol Chem"},{"key":"1026_CR16","doi-asserted-by":"publisher","first-page":"31857","DOI":"10.18632\/oncotarget.5273","volume":"6","author":"J Hou","year":"2015","unstructured":"Hou J, Deng M, Li X, Liu W, Chu X, Wang J, et al. Chaperone gp96 mediates ER-\u03b136 cell membrane expression. Oncotarget. 2015;6:31857\u201367. https:\/\/doi.org\/10.18632\/oncotarget.5273.","journal-title":"Oncotarget"},{"key":"1026_CR17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ijc.29405","volume":"137","author":"X Li","year":"2015","unstructured":"Li X, Sun L, Hou J, Gui M, Ying J, Zhao H, et al. Cell membrane gp96 facilitates HER2 dimerization and serves as a novel target in breast cancer. Int J Cancer. 2015;137:512\u201324. https:\/\/doi.org\/10.1002\/ijc.29405.","journal-title":"Int J Cancer"},{"key":"1026_CR18","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1158\/0008-5472.CAN-10-2887","volume":"71","author":"K Farin","year":"2011","unstructured":"Farin K, Schokoroy S, Haklai R, Cohen-Or I, Elad-Sfadia G, Reyes-Reyes ME, et al. Oncogenic synergism between ErbB1, nucleolin, and mutant Ras. Cancer Res. 2011;71:2140\u201351. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2887.","journal-title":"Cancer Res"},{"key":"1026_CR19","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/onc.2010.458","volume":"30","author":"XT Zhang","year":"2011","unstructured":"Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, Wang ZY. A positive feedback loop of ER-\u03b136\/EGFR promotes the malignant growth of ER-negative breast cancer cells. Oncogene. 2011;30:770\u201380. https:\/\/doi.org\/10.1038\/onc.2010.458.","journal-title":"Oncogene"},{"key":"1026_CR20","doi-asserted-by":"publisher","first-page":"4729","DOI":"10.1182\/blood-2012-12-471094","volume":"121","author":"JF Wise","year":"2013","unstructured":"Wise JF, Berkova Z, Mathur R, Zhu H, Braun FK, Tao RH, et al. Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. Blood. 2013;121:4729\u201339. https:\/\/doi.org\/10.1182\/blood-2012-12-471094.","journal-title":"Blood"},{"key":"1026_CR21","doi-asserted-by":"publisher","first-page":"9463","DOI":"10.1021\/bi060756w","volume":"45","author":"T Herren","year":"2006","unstructured":"Herren T, Burke TA, Das R, Plow EF. Identification of histone H2B as a regulated plasminogen receptor. Biochemistry. 2006;45:9463\u201374. https:\/\/doi.org\/10.1021\/bi060756w.","journal-title":"Biochemistry"},{"key":"1026_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100878","volume":"14","author":"MA Albaret","year":"2021","unstructured":"Albaret MA, Par\u00e9 A, Malet L, De Souza G, Lavergne E, Goga D, et al. Combined proteomic and transcriptomic approaches reveal externalized keratin 8 as a potential therapeutic target involved in the invasiveness of head and neck cancers. Transl Oncol. 2021;14:100878. https:\/\/doi.org\/10.1016\/j.tranon.2020.100878.","journal-title":"Transl Oncol"},{"key":"1026_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2015.12.004","volume":"37\u201338","author":"I Orsolic","year":"2016","unstructured":"Orsolic I, Jurada D, Pullen N, Oren M, Eliopoulos AG, Volarevic S. The relationship between the nucleolus and cancer: Current evidence and emerging paradigms. Semin Cancer Biol. 2016;37\u201338:36\u201350. https:\/\/doi.org\/10.1016\/j.semcancer.2015.12.004.","journal-title":"Semin Cancer Biol"},{"key":"1026_CR24","doi-asserted-by":"publisher","unstructured":"Graifer D, Malygin A, Shefer A. Tamkovich S. Ribosomal proteins as exosomal cargo: random passengers or crucial players in carcinogenesis? Adv Biol. https:\/\/doi.org\/10.1002\/adbi.202400360.","DOI":"10.1002\/adbi.202400360"},{"key":"1026_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcae029","volume":"6","author":"S Ramalho","year":"2024","unstructured":"Ramalho S, Dopler A, Faller WJ. Ribosome specialization in cancer: a spotlight on ribosomal proteins. NAR Cancer. 2024;6:zcae029. https:\/\/doi.org\/10.1093\/narcan\/zcae029.","journal-title":"NAR Cancer"},{"key":"1026_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molcel.2009.03.006","volume":"34","author":"JR Warner","year":"2009","unstructured":"Warner JR, McIntosh KB. How common are extraribosomal functions of ribosomal proteins? Mol Cell. 2009;34:3\u201311. https:\/\/doi.org\/10.1016\/j.molcel.2009.03.006.","journal-title":"Mol Cell"},{"key":"1026_CR27","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/biom14121565","volume":"14","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Ruan S, Li Y, Qi T, Qi Y, Huang Y, et al. The influence of extra-ribosomal functions of eukaryotic ribosomal proteins on viral infection. Biomolecules. 2024;14:1565. https:\/\/doi.org\/10.3390\/biom14121565.","journal-title":"Biomolecules"},{"key":"1026_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1349-7006.2010.01814.x","volume":"102","author":"L Marzocchella","year":"2011","unstructured":"Marzocchella L, Sini V, Buonomo O, Orlandi A, Masuelli L, Bonanno E, et al. Spontaneous immunogenicity of ribosomal P0 protein in patients with benign and malignant breast lesions and delay of mammary tumor growth in P0-vaccinated mice. Cancer Sci. 2011;102:509\u201315. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01814.x.","journal-title":"Cancer Sci"},{"key":"1026_CR29","first-page":"1301","volume":"31","author":"R Bei","year":"2007","unstructured":"Bei R, Masuelli L, Trono P, Orvietani PL, Losito S, Marzocchella L, et al. The ribosomal P0 protein induces a spontaneous immune response in patients with head and neck advanced-stage carcinoma that is not dependent on its overexpression in carcinomas. Int J Oncol. 2007;31:1301\u20138.","journal-title":"Int J Oncol"},{"key":"1026_CR30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/ijc.30425","volume":"140","author":"NC Synnott","year":"2017","unstructured":"Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O'Donovan N, et al. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? Int J Cancer. 2017;140:234\u201346. https:\/\/doi.org\/10.1002\/ijc.30425.","journal-title":"Int J Cancer"},{"key":"1026_CR31","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ccr.2012.03.042","volume":"21","author":"X Yu","year":"2012","unstructured":"Yu X, Vazquez A, Levine AJ, Carpizo DR. Allele-specific p53 mutant reactivation. Cancer Cell. 2012;21:614\u201325. https:\/\/doi.org\/10.1016\/j.ccr.2012.03.042.","journal-title":"Cancer Cell"},{"key":"1026_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1290","volume":"7","author":"A Rehman","year":"2005","unstructured":"Rehman A, Chahal MS, Tang X, Bruce JE, Pommier Y, Daoud SS. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. Breast Cancer Res. 2005;7:R765. https:\/\/doi.org\/10.1186\/bcr1290.","journal-title":"Breast Cancer Res"},{"key":"1026_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11390","volume":"7","author":"E Nicolas","year":"2016","unstructured":"Nicolas E, Parisot P, Pinto-Monteiro C, de Walque R, De Vleeschouwer C, Lafontaine DLJ. Involvement of human ribosomal proteins in nucleolar structure and p53-dependent nucleolar stress. Nat Commun. 2016;7:11390. https:\/\/doi.org\/10.1038\/ncomms11390.","journal-title":"Nat Commun"},{"key":"1026_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fpls.2021.607157","volume":"12","author":"W Xiong","year":"2021","unstructured":"Xiong W, Lan T, Mo B. Extraribosomal functions of cytosolic ribosomal proteins in plants. Front Plant Sci. 2021;12:607157. https:\/\/doi.org\/10.3389\/fpls.2021.607157.","journal-title":"Front Plant Sci"},{"key":"1026_CR35","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0968-0004(96)20011-8","volume":"21","author":"IG Wool","year":"1996","unstructured":"Wool IG. Extraribosomal functions of ribosomal proteins. Trends Biochem Sci. 1996;21:164\u20135.","journal-title":"Trends Biochem Sci"},{"key":"1026_CR36","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.3389\/fonc.2020.01730","volume":"10","author":"C Li","year":"2020","unstructured":"Li C, Ge M, Chen D, Sun T, Jiang H, Xie Y, et al. RPL21 siRNA blocks proliferation in pancreatic cancer cells by inhibiting DNA replication and inducing G1 arrest and apoptosis. Front Oncol. 2020;10:1730. https:\/\/doi.org\/10.3389\/fonc.2020.01730.","journal-title":"Front Oncol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01026-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:27:14Z","timestamp":1782826034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01026-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1026"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01026-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.03.25.645355","asserted-by":"object"}]},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The cohort of TNBC was composed of 10 samples (PGEB platform, Cancer Research Centre of Lyon\/Centre L\u00e9on B\u00e9rard, Lyon, FRANCE). The material used in the study was collected in agreement with all applicable laws, rules, and requests of French and European government authorities. Informed consent was taken from patients. Ethics approval of the study was obtained from the Ethical Review Board of the Center L\u00e9on B\u00e9rard (CMT n\u00b0 2025-23).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}